<DOC>
	<DOCNO>NCT01759784</DOCNO>
	<brief_summary>ALS debilitate disease vary etiology characterize rapidly progressive weakness , muscle atrophy fasciculation , muscle spasticity , difficulty speaking ( dysarthria ) , difficulty swallowing ( dysphagia ) , difficulty breathing ( dyspnea ) . ALS common five motor neuron diseases.Riluzole ( Rilutek ) treatment find improve survival modest extent . It lengthen survival several month , may great survival benefit bulbar onset . It also extend time person need ventilation support.Stem cell transplantation new hopeful way improve patient condition reduce period disability .</brief_summary>
	<brief_title>Intraventricular Transplantation Mesenchymal Stem Cell Patients With ALS</brief_title>
	<detailed_description>In study purpose evaluate safety intraventricular injection bone marrow derive mesenchymal stem cell.the patient eligible , underwent bone marrow aspiration.after cell separation preparation , patient underwent mesenchymal stem cell intraventricular injection stereotaxis.after injection observe ICU monitor adverse event ( allergic neurological side effect ) .patients follow 1th,3th ,6th 12 month injection time parameter check : ALS-FRS , EMG-NCV , FVC , side effect check list .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Age:1865 gender duration disease &lt; 2 year FVC &gt; 40 % ALSFRS &gt; 26 neurological psychiatric concomitant disease concomitant systemic disease treatment corticosteroid , Ig , immunosuppressive 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>mesenchymal stem cell intraventricular injection ALS</keyword>
</DOC>